Predictive biomarkers for capecitabine benefit in breast cancer patients with residual disease after neoadjuvant chemotherapy

Predictive biomarkers for capecitabine benefit in breast cancer patients with residual disease after neoadjuvant chemotherapy - JBCRG-04(CREATE-X) TR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040260

Enrollment

606

Registered

2020-04-28

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who were registered A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy (JBCRG-04) trial

Exclusion criteria

Exclusion criteria: This study is a retrospective observational study, carried out by the opt-out method of our website.

Design outcomes

Primary

Measure	Time frame
Correlation between tumor immune microenvironment and 1)-6) 1) Patient characteristics, Pathological signature such as ER, HER2 status. 2) Disease free survival 3) Overall survival 4) Incidence of local recurrence 5) Incidence of distant metastasis 6) Clinical response rate of neoadjuvant chemotherapy	—

Countries

Japan

Contacts

Public ContactKosuke Kawaguchi

Kyoto University Graduate School of Medicine Department of breast surgery

kkosuke@kuhp.kyoto-u.ac.jp075-751-3660

Outcome results